Furthermore, Tamoxifen treated ER (+) breast cancers often increase BCL-2 and BCL-XL levels which leads to a decreased acute tumor response and ultimately to a long-term resistance to Tamoxifen [22]. This evidence concerns the gene BCL2L1 and breast carcinoma.